NDA 211765 · Abbvie
Ubrelvy
Ubrogepant · Oral · Calcitonin Gene-related Peptide Receptor Antagonist
NovelLast checked: Nov 19, 2026Latest source record: Jun 5, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2019
Dec 23, 2019
Approved uses
1
Original approval plus efficacy supplements
Registered trials
18
7 Phase 3, 1 recruiting
FAERS reports
6,366
2,277 serious, 107 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 29, 2026.
UBRELVY is indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use UBRELVY is not indicated for the preventive treatment of migraine. UBRELVY is a calcitonin gene-related peptide receptor antagonist indicated for the acute treatment of migraine with or without aura in adults. ( 1 ) Limitations of Use UBRELVY is not indicated for the preventive treatment of migraine. ( 1 )
Mechanism: Ubrogepant is a calcitonin gene-related peptide receptor antagonist.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
2 products under this application
- UBRELVY · UBROGEPANT 50MG · TABLET, ORAL · Prescription
- UBRELVY · UBROGEPANT 100MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Ubrogepant" as an intervention, any sponsor and status, largest first.
- Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of MigrainePivotal-lookingCompleted
AllerganAbbVie (ABBV)
NCT02867709 · 1,686 participants · Start Aug 26, 2016 · Primary completion Jan 25, 2018
Drug: Ubrogepant; Placebo-matching Ubrogepant · For: Migraine, With or Without Aura
Sites: Birmingham, Alabama; Chandler, Arizona; Phoenix, Arizona · 109 sites in all
- Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of MigrainePivotal-lookingCompleted
AllerganAbbVie (ABBV)
NCT02828020 · 1,672 participants · Start Jul 22, 2016 · Primary completion Dec 13, 2017
Drug: Ubrogepant; Placebo-matching Ubrogepant · For: Migraine, With or Without Aura
Sites: Mesa, Arizona; Phoenix, Arizona; Tucson, Arizona · 90 sites in all
- An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of MigrainePivotal-lookingCompleted
AllerganAbbVie (ABBV)
NCT02873221 · 1,254 participants · Start Sep 13, 2016 · Primary completion Aug 2, 2018
Drug: Ubrogepant; Placebo-matching Ubrogepant and 1 more · For: Migraine, With or Without Aura
Sites: Birmingham, Alabama; Chandler, Arizona; Mesa, Arizona · 177 sites in all
- Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)Pivotal-lookingEnrolling by invitation
AbbVieAbbVie (ABBV)
NCT05127954 · 1,200 participants (planned) · Start Jan 14, 2022 · Primary completion Jan 2028
Drug: Ubrogepant · For: Migraine
Sites: Huntsville, Alabama; Saraland, Alabama; Little Rock, Arkansas · 113 sites in all
- Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)Pivotal-lookingRecruiting
AbbVieAbbVie (ABBV)
NCT05125302 · 1,059 participants (planned) · Start Jan 13, 2022 · Primary completion May 2027
Drug: Ubrogepant; Placebo-Matching Ubrogepant · For: Migraine
Sites: Huntsville, Alabama; Saraland, Alabama; Phoenix, Arizona · 129 sites in all
- A Dose-Finding Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-006)Pivotal-lookingCompleted
AllerganAbbVie (ABBV)
NCT01613248 · 834 participants · Start Jul 1, 2012 · Primary completion Dec 1, 2012
Drug: MK-1602; Placebo-matching MK-1602 and 1 more · For: Migraine
- Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult ParticipantsPivotal-lookingCompleted
AbbVieAbbVie (ABBV)
NCT04492020 · 518 participants · Start Aug 21, 2020 · Primary completion Apr 19, 2022
Drug: Ubrogepant 100 mg; Placebo · For: Migraine
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 73 sites in all
- Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual MigrainePivotal-lookingActive, not recruiting
AbbVieAbbVie (ABBV)
NCT06417775 · 496 participants (planned) · Start Sep 10, 2024 · Primary completion Nov 2027
Drug: Ubrogepant; Placebo for Ubrogepant · For: Migraine
Sites: Birmingham, Alabama; Huntsville, Alabama; Chandler, Arizona · 106 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective1,069
- migraine921
- headache575
- nausea553
- fatigue389
- off label use300
- dizziness282
- pain280
- product dose omission issue240
- vomiting226
- pruritus188
- diarrhoea178
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2015 | 1 |
| 2016 | 9 |
| 2017 | 1 |
| 2018 | 4 |
| 2019 | 17 |
| 2020 | 449 |
| 2021 | 643 |
| 2022 | 1,125 |
| 2023 | 947 |
| 2024 | 1,053 |
| 2025 | 1,096 |
| 2026 | 1,021 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Ubrelvy (Ubrogepant)
2024 spending
$430M
Beneficiaries
83,437
328,213 claims
Per beneficiary
$5,148
$102.07 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $46,916,765 |
| 2021 | $132,378,260 |
| 2022 | $232,438,290 |
| 2023 | $314,665,016 |
| 2024 | $429,537,898 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative effects of drug interventions for the acute management of migraine episodes in adults: systematic review and network meta-analysis.
Karlsson WK, Ostinelli EG, Zhuang ZA, et al. · BMJ 2024 · Systematic Review, Comparative Study
- Comparison of New Pharmacologic Agents With Triptans for Treatment of Migraine: A Systematic Review and Meta-analysis.
Yang CP, Liang CS, Chang CM, et al. · JAMA Netw Open 2021 · Research Support, Non-U.S. Gov't, Systematic Review
- Ubrogepant for the treatment of migraine attacks during the prodrome: a phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial in the USA.
Dodick DW, Goadsby PJ, Schwedt TJ, et al. · Lancet 2023 · Randomized Controlled Trial, Multicenter Study
- Safety and tolerability of ubrogepant for the acute treatment of migraine in participants taking atogepant for the preventive treatment of episodic migraine: Results from the TANDEM study.
Ailani J, Lipton RB, Blumenfeld AM, et al. · Headache 2025 · Clinical Trial, Phase IV, Multicenter Study
- Effect of Ubrogepant on Patient-Reported Outcomes When Administered During the Migraine Prodrome: Results From the Randomized PRODROME Trial.
Lipton RB, Harriott AM, Ma JY, et al. · Neurology 2024 · Randomized Controlled Trial, Multicenter Study
- Efficacy of lasmiditan, rimegepant and ubrogepant for acute treatment of migraine in triptan insufficient responders: systematic review and network meta-analysis.
Laohapiboolrattana W, Jansem P, Anukoolwittaya P, et al. · J Headache Pain 2024 · Systematic Review, Network Meta-Analysis
Sponsor: AbbVie
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.